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Conflict of interest occurs when circumstances create a risk
that a person’s professional judgment or actions regarding a
primary interest will be unduly influenced by a secondary
interest. This has recently become a focus of attention for
physicians and physicians’ groups as well as for the lay press
and some politicians—particularly financial conflict of in-
terest (FCOI), which occurs when monetary or material
inducements have (or are perceived to have) the potential to
influence impartial judgment. However, the paper by Aneja
et al. (1) in this issue of the Journal presents findings that
may prove surprising to some. In an analysis of randomized
See page 1137
clinical trials whose results were published in 1 of 3 high-impact
journals (The New England Journal of Medicine, Lancet, and
JAMA), Aneja et al. (1) found that authors with an acknowl-
edged FCOI in addition to the primary research grant or
contract (i.e., payments for consultancies or lectures, stock
ownership, or employment) did not produce study manu-
scripts that were more likely to show positive results for the
experimental therapy. This finding remained consistent
even when FCOI reporting increased directly with the level
of industry funding of the trial. The type of FCOI and the
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Duke Translational Medicine Institute and the Division of Cardiology,
Department of Medicine, Duke University Medical Center, Durham, North
Carolina. For the period from 2010 through 2013, Dr. Califf has received research
grants that partially support his salary from Amylin, Johnson & Johnson (Scios),
Merck/Schering Plough, Schering Plough Research Institute, Novartis Pharma,
Bristol-Myers Squibb Foundation, Aterovax, Bayer, Roche, Lilly, and Schering
Plough; all grants are paid to Duke University. Dr. Califf also consults for
TheHeart.org, Johnson & Johnson, Scios, Kowa Research Institute, Nile, Parkview,
Orexigen Therapeutics, Pozen, WebMD, Bristol-Myers Squibb Foundation, Astra-
Zeneca, Bayer-OrthoMcNeil, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi
Sankyo, GlaxoSmithKline, Li Ka Shing Knowledge Institute, Medtronic, Merck,
Novartis, Sanofi-Aventis, XOMA, University of Florida, Pfizer, Roche, and Servier
International, DSI-Lilly, Janssen R&D, CV Sight, Regeneron, and Gambro. All
income from these consultancies is donated to nonprofit organizations, with most
going to the clinical research fellowship fund of the Duke Clinical Research Institute.
Dr. Califf holds equity in Nitrox LLC, N30 Pharma, and Portola. A complete and
continuously updated list of disclosure information for Dr. Califf is available at
https://dcri.org/about-us/conflict-of-interest.use of a surrogate endpoint in the relevant clinical trial were
not statistically associated with greater likelihood of positive
result reporting, although the p value for surrogate versus
clinical endpoint was 0.051.
These are provocative findings, but their generalizability
is limited by the methods used in the study. First, the
articles examined by the authors were restricted to random-
ized trials published in 3 very high-impact general biomed-
ical journals. Such journals are hardly representative of the
general medical literature, because they are highly selective
and typically publish findings from large, adequately pow-
ered trials that tend to be clinically interesting regardless of
whether the results are positive or negative. We know that
many clinical trials are not reported at all (2–4), and it is
likely that even for most trials that are reported, the less
prestigious journals in which they are published would be
less likely to insist on accurate characterization of the results
than the 3 prestigious journals that formed the substrate for
the present investigation.
There is a significant body of literature indicating that
self-reported FCOI is inaccurate (5), and as noted above,
there is reason to believe that such inaccurate reporting may
be more the case in less authoritative medical journals.
Unfortunately, the authors did not interrogate the authors
or the public record independently to clarify this issue. They
would have made a much more convincing case if the
veracity of the self-reports had been validated.
The National Institute of Medicine’s ClinicalTrials.gov
registry could play an important role in this regard by
serving as a key instrument for research concerning publi-
cation bias and FCOI reporting. As of September 2007,
there is a legal requirement to register almost all clinical
trials relevant to United States practice; as of 2008, report-
ing of trial results is required. Given this level of available
detail, the 3 critical dependent variables in such an investi-
gation would be: 1) whether the results were published; 2)
whether the results were positive, neutral, negative, or
inconclusive for the new treatment; and 3) whether the
interpretation in the publication was accurate, inappropri-
ately more favorable than the results would warrant, or
inappropriately less favorable than the interpretation com-
ing from an independent review. Here again, it is likely that
if biased interpretation exists, it may be more likely to be
found in less prestigious journals, because the journals
investigated in the study by Aneja et al. (1) provide robust
editorial oversight of the introduction and discussion sec-
tions of the manuscript. However, recent work suggests that
retractions are at least as common in more prestigious
journals, although the underlying reasons for such findings
are not yet clear (6,7).
One important step that would help to unravel this issue
would be more uniform reporting of conflicts of interest,
both to provide more understandable information and to
reduce the burden on authors and investigators. Lichter and
McKinney (8), building on a recommendation from the
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creating a central mechanism for reporting FCOI.
The complexity of this issue can be appreciated in the
context of discussion about a manuscript purporting to show
that FCOI among Food and Drug Administration Advisory
Committee members led to inappropriately positive votes
regarding new therapies, because conflicted members more
often voted for approval (9). Although the authors found
that this relationship pertained only to competitor drugs for
the drug undergoing evaluation, the authors de-emphasized
this aspect, leading to the study being cited as supporting an
industry bias. However, when the Food and Drug Admin-
istration looked more closely, it emphasized the key finding
that conflicted members actually were not more likely to
vote for approval of the product for which they had a
conflict, but they indeed were more likely to vote positively
for a competitors’ product (10). Unfortunately, the JAMA
reference is still widely quoted for the general finding,
whereas the more nuanced interpretation by the Food and
Drug Administration itself is buried on its website.
An additional factor that should be considered is nonfi-
nancial conflict of interest. Investigators who hold strong
beliefs or who are engaged in competing work often can
affect the interpretation of a study’s results or the editorial
perspective taken by a journal. These types of conflicts are
well described, but they are not evaluated as often because
they are less overt and are harder to quantify than FCOI.
As is the case in many other arenas, the field of biomed-
ical ethics could benefit from more empirical investigation.
Suppositions and news reports can raise issues, and in many
cases anecdotal accounts and opinions serve a vital function.
But all too often, they give misleading impressions that
would be dispelled by a dispassionate and comprehensive
view. Despite the flaws in the study by Aneja et al. (1), they
have performed a valuable service by pointing out that, at
least in the restricted setting of 3 top-tier general biomedical
journals, the existence of reported FCOI is not correlated
with significant differences in positive or negative study
outcomes. The comprehensive availability of journal con-
tents, combined with the increasingly granular data availablevia the ClinicalTrials.gov registry, could enable both the
clinical community and patient advocates to monitor bias—
including bias arising from less obvious sources than finan-
cial conflicts. A systematic approach to interrogating this
issue, coupled with increasingly comprehensive sources for
data analysis, has the potential to reduce the amount of
conflicting information about conflicts of interest.
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